THE-EARTHSHOT-PRIZE
17.9.2021 19:03:10 CEST | Business Wire | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet.
Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet.
“I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.”
Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Like President John F. Kennedy’s ‘Moonshot’ did almost 60 years ago, the Prize aims to unleash an unprecedented wave of innovation and leadership to tackle our greatest environmental challenges. The Earthshot Prize will be awarded every year for the next decade, discovering a total of 50 Winners.
Five of these 15 Finalists will be awarded The Earthshot Prize and will win £1million in Prize funding for the best solutions of the five Earthshot goals: Protect and Restore Nature; Clean our Air; Revive our Oceans; Build a Waste-free World; and Fix our Climate . The Winners will be announced during an awards ceremony on 17th October from London’s Alexandra Palace, broadcast in the UK on BBC One and globally on Discovery+.
The Earthshot Prize Finalists for 2021 are:
Protect and Restore Nature:
- Pole Pole Foundation, Democratic Republic of Congo
An inspiring community-led model of conservation that protects gorillas and local livelihoods.
- The Republic of Costa Rica
A pioneering scheme paying local citizens to restore natural ecosystems that has led to a revival of the rainforest.
- Restor, Switzerland
A ground-breaking online platform connecting and empowering local conservation projects.
Clean our Air:
- The Blue Map App, China
China’s first public environmental database enabling citizens to hold polluters to account.
- Takachar, India
A pioneering technology to create profitable products from agricultural waste and put a stop to the burning of crops.
- Vinisha Umashankar, India
A 14-year-old innovator and activist who has designed a solar-powered ironing cart with the potential to improve air quality across India.
Revive our Oceans:
- Coral Vita, Bahamas
A truly cutting-edge breakthrough in coral farming that can restore our world’s dying coral reefs.
- Living Seawalls, Australia
Innovative and replicable seawall panels bringing marine life back to coastal sea defences.
- Pristine Seas, USA
An unprecedented global conservation programme protecting 6.5 million square km of the world’s ocean.
Build a Waste-Free World:
- The City of Milan Food Waste Hubs, Italy
A city-wide initiative that has dramatically cut waste while tackling hunger.
- Sanergy, Kenya
A circular sanitation solution that converts human waste into safe products for local farmers.
- WOTA BOX, Japan
A tiny water treatment plant that turns 98% of wastewater into clean water.
Fix our Climate:
- AEM Electrolyser, Thailand/Germany/Italy
An ingenious green hydrogen technology developed to transform how we power our homes and buildings.
- Reeddi Capsules, Nigeria
Solar-powered energy capsules making electricity affordable and accessible in energy-poor communities.
- SOLbazaar, Bangladesh
The world’s first peer-to-peer energy exchange network in a country on the front-line of climate change.
All 15 Finalists will receive support from The Earthshot Prize Global Alliance Members, an unprecedented network of global businesses, who will help scale their solutions for even greater impact.
Of these 15 Finalists, the five Winners will be selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
In the run-up to the prize-giving ceremony on 17 October, BBC and Discovery will release a 5-part documentary series THE EARTHSHOT PRIZE: REPAIRING OUR PLANET, featuring Earthshot Prize Council Members including Prince William, Shakira Mebarak, Daniel Alves Da Silva and Sir David Attenborough.
For more information about the Finalists and The Earthshot Prize, visit: www.earthshotprize.org , email Claire Straw: TEPmedia@freuds.com, download media pack here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005454/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom